Tuesday 18 May 2021

Digital Transformation and Regulatory Considerations for Biopharmaceutical and Healthcare Manufacturers, Volume 2: Digital Data, Insights, Metrics and Analytics

This second of two volumes details how pharmaceutical and healthcare manufacturers have been embracing digital technologies as part of the transformation of their business models. It contextualizes current developments and future advancements in terms of the COVID-19 situation of 2020 and specific measures that were taken.

Topics and laboratory functions that will be explored include:

  • New model healthcare
  • Ways to use digital data, including root cause investigations
  • Office technology
  • Protecting ownership security
  • E-learning and virtual inspections
  • And many more

The first volume of this two-part collection addresses building a digital company, big data analytics, advances in Process Analytical Technology electronic batch records, Block Chain, and more. Taken together, these volumes provide a clear picture of where things currently stand, where they are likely to develop, and the challenges that digital technology adopters face, in terms of practicalities and in maintaining GMP compliance.

See: https://www.pda.org/bookstore/product-detail/5949-digital-transformation-volume-2

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers